Introduction {#Sec1}
============

Ankylosing spondylitis (AS), or radiographic axial spondyloarthritis, is a potentially debilitating inflammatory disease of the sacroiliac joint and spine that impacts 0.5--1% of the population \[[@CR1], [@CR2]\]. Patients with AS show evidence of sacroiliitis on plain films of the sacroiliac joints according to specific criteria \[[@CR3]\]. These disease characteristics are important for the diagnosis of AS. However, there are many other facets of AS that affect patients profoundly. Patients suffer with pain, fatigue, and stiffness, plus physical limitations, all of which impact patients' quality of life (QoL) \[[@CR4]\]. Several types of therapy are recommended, including exercise, physical therapy, nonsteroidal anti-inflammatory drugs, and biologic disease-modifying antirheumatic drugs (bDMARDs) \[[@CR5]\]. While tumor necrosis factor inhibitors (TNFi) improve symptoms for many patients, up to 40% of patients with AS do not respond well or sustain a response to these medications \[[@CR6]--[@CR10]\].

Several new bDMARDs are in development or approved, including those that bind interleukin 17 (IL-17), a key cytokine in the pathogenesis of AS \[[@CR11]\]. Ixekizumab is a humanized immunoglobulin G4 monoclonal antibody which targets IL-17A, one of the six members of the IL-17 family \[[@CR12]\]. The results of two recently completed clinical trials demonstrated ixekizumab's efficacy in treating patients with AS: COAST-V tested ixekizumab in patients who had never been treated with a bDMARD (bDMARD-naïve), and COAST-W tested ixekizumab in patients who had not responded to or had been intolerant of one or two TNFis (TNFi-experienced) \[[@CR13], [@CR14]\].

A commonly used measure of AS treatment efficacy in clinical trials is the Assessment of Spondyloarthritis International Society response criteria, including ASAS20, ASAS40, and ASAS partial remission \[[@CR15]\]. Four domains are used for the ASAS clinical trial treatment response assessments: patient global (patient global assessment of disease), spinal pain, function (as assessed by the Bath Ankylosing Spondylitis Functional Index \[BASFI\]), and inflammation (stiffness) \[[@CR15]\]. The ASAS treatment response domains rely on patient-reported outcomes, highlighting the importance of a patient's own health assessment for evaluating the efficacy of AS treatments.

Historically, clinical trials for bDMARDs have used ASAS20 as the primary endpoint for determining efficacy in AS \[[@CR16]--[@CR19]\]. The COAST-V and COAST-W trials of ixekizumab efficacy in AS used ASAS40, a higher standard, as the primary endpoint. COAST-V and COAST-W reported statistically significantly higher proportions of patients achieving ASAS40 in ixekizumab treatment groups versus placebo \[[@CR13], [@CR14]\]. Although the ASAS response is of great value in the context of clinical trials, in daily clinical practice, physicians focus on each individual's clinical symptoms rather than calculating an ASAS response. Thus, this report seeks to translate the clinical impact of achieving an ASAS40 response into the individual patient-reported outcomes utilized in clinical practice. The goals of this study were (a) to measure improvement in ixekizumab-treated patients both in the ASAS response criteria domains and in other outcomes, and (b) to quantify the incremental improvement in patient-reported outcomes for patients who achieve ASAS40 compared to those who did not achieve ASAS20.

Methods {#Sec2}
=======

Trial Design {#Sec3}
------------

The COAST-V and COAST-W trial designs have been published previously \[[@CR13], [@CR14]\]. Briefly, COAST-V and COAST-W were phase 3, multicenter, randomized, double-blind, placebo-controlled trials. COAST-V contained an active-reference arm, in which patients received adalimumab \[[@CR14]\]. COAST-V and COAST-W were conducted at 84 and 106 sites in 12 and 15 countries, respectively, across North America, South America, Europe, and Asia. Each study was approved by ethical review boards at each site before the start of the studies. COAST-V and COAST-W were registered on ClinicalTrials.gov as NCT02696785 and NCT02696798, respectively. All procedures performed in these studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committees at all sites where these studies were conducted and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. The master ethics committee was Schulman Associates IRB, Cincinnati, OH, USA. The full lists of investigators and sites are provided in the primary manuscript supplements \[[@CR13], [@CR14]\]. Informed consent was obtained from all individual participants included in the studies.

Trial Participants {#Sec4}
------------------

COAST-V and COAST-W included patients who fulfilled the ASAS criteria for radiographic axial spondyloarthritis \[[@CR13]--[@CR15]\]. Post hoc analysis showed that these patients also fulfilled the modified New York criteria for AS \[[@CR20]\]. Patients in COAST-V and COAST-W had long-standing symptoms of AS for a mean (standard deviation, SD) of 16.0 (10.3) and 18.4 (11.1) years, and had been diagnosed 7.7 (8.4) and 11.6 (9.1) years prior to the study, respectively \[[@CR13], [@CR14]\]. Mean (SD) baseline Ankylosing Spondylitis Disease Activity Scores (ASDAS) were 3.8 (0.8) for COAST-V patients and 4.1 (0.8) for COAST-W patients \[[@CR13], [@CR14]\], which indicates very high disease activity in the populations included in the trials (ASDAS \> 3.5) \[[@CR21]\]. Patients had mean (SD) baseline C-reactive protein (CRP) scores of 13.5 (17.1) and 17.8 (26.6) mg/L, with 64% and 66% having elevated CRP at baseline (CRP \> 5 mg/L), for COAST-V and COAST-W, respectively \[[@CR13], [@CR14]\]. COAST-V patients had no history of biologic or other immunomodulatory agents, including investigational therapies (bDMARD-naïve) \[[@CR14]\]. COAST-W patients had prior treatment with one or two TNFi and had discontinued at least one TNFi due to inadequate response or intolerance (TNFi-experienced) \[[@CR13]\]. A majority of the TNFi-experienced patients (89.9%) had responded inadequately to at least one TNFi.

Randomization and Blinding {#Sec5}
--------------------------

In COAST-V, 341 patients were randomized 1:1:1:1 to receive subcutaneous injections of 80 mg ixekizumab every 2 weeks (Q2W, *n* = 83), 80 mg ixekizumab every 4 weeks (Q4W; *n* = 81), 40 mg adalimumab Q2W (*n* = 90), or placebo Q2W (*n* = 87) \[[@CR14]\]. In COAST-W, 316 patients were randomized 1:1:1 to receive subcutaneous injections of 80 mg ixekizumab Q2W (*n* = 98), 80 mg ixekizumab Q4W (*n* = 114), or placebo Q2W (*n* = 104) \[[@CR13]\]. Patients receiving ixekizumab in both trials were randomized 1:1 to receive a starting dose of either 80 mg or 160 mg ixekizumab at week 0 \[[@CR13], [@CR14]\].

Assessments {#Sec6}
-----------

An ASAS40 response was the primary endpoint for both COAST-V and COAST-W. ASAS40 is defined as a ≥ 40% improvement and an absolute improvement from baseline of ≥ 2 units (range 0--10) in ≥ 3 of the 4 domains without any worsening in the remaining domain \[[@CR15]\]. Secondary endpoints included ASAS20 responses and changes from baseline in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) scores, BASFI scores, and the Medical Outcomes Study 36-Item Short-Form Health Survey Physical Component Summary version 2 (SF-36 PCS). An ASAS20 response is defined as ≥ 20% improvement and an absolute improvement from baseline of ≥ 1 units (range 0--10) in ≥ 3 of the 4 domains and no worsening of ≥ 20% and ≥ 1 unit (range 0--10) in the remaining domain \[[@CR15]\]. Both BASDAI question 1 (Q1) and a second independently developed measure were used to measure fatigue. The second measure, the Fatigue Numeric Rating Scale (NRS), assessed the patient's level of fatigue in the last 24 h from 0 (no fatigue) to 10 (as bad as you can imagine) \[[@CR22]\]. Pain was assessed as described in the*ASAS Handbook* \[[@CR15]\], asking patients the following two questions about their pain in the last week: (1) "How much pain of your spine due to ankylosing spondylitis do you have?" and (2) "How much pain of your spine due to ankylosing spondylitis do you have at night?" The answers to the two pain questions were recorded and a rating of between 0 (no pain) and 10 (most severe pain) was assigned. Results from the first pain question were used to derive responses for the calculation of pain in ASAS20 and ASAS40. Patient global, BASFI, and inflammation (the average of BASDAI Q5 \[intensity of morning stiffness\] and Q6 \[duration of morning stiffness\]) scores were used to calculate the other three domains for ASAS20 and ASAS40 \[[@CR15]\]. Each domain received a score from 0 to 10. Unless indicated otherwise, data were collected at each study visit (baseline and weeks 1, 2, 4, 8, 12, and 16). SF-36 PCS data were collected at baseline and weeks 4, 8, and 16. Fatigue NRS and Jenkins Sleep Evaluation Questionnaire (JSEQ) data were collected at baseline and weeks 8 and 16 \[[@CR23]\]. Higher JSEQ scores indicate an increased frequency of disrupted sleep \[[@CR23]\].

Statistical Analyses {#Sec7}
--------------------

For comparisons between treatment groups, changes from baseline for the ASAS treatment response domains (patient global, spinal pain, BASFI, inflammation \[BASDAI Q5 and Q6\]) and other patient-reported outcomes (spinal pain at night, fatigue \[BASDAI Q1 and NRS\], JSEQ, BASDAI, and SF-36 PCS) were analyzed using a mixed-effects model for repeated measures. No statistical comparisons were performed between adalimumab and ixekizumab because the adalimumab was included as an active reference. Post hoc association analyses between ASAS response status and change in patient-reported outcome measures were conducted by pooling all patients (placebo and adalimumab groups included) into three groups: patients who did not achieve ASAS20 (ASAS20 nonresponders), patients who achieved ASAS20 but not ASAS40, and patients who achieved ASAS40. Data from the two trials were kept separate in this analysis in order to determine whether there were differences in responses between bDMARD-naïve and TNFi-experienced patients. Changes from baseline in pain, fatigue (NRS), JSEQ, and SF-36 PCS scores were compared between ASAS response groups using analysis of covariance (ANCOVA) after adjusting for baseline values, age, and gender. Post hoc comparisons were conducted with Scheffe's correction. Missing data were imputed using nonresponder imputation for all categorical endpoints and modified baseline observation carried forward for the ANCOVA model. Statistical analyses were performed using SAS version 9.2 or higher. Nominal *p* values are shown.

Results {#Sec8}
=======

Baseline disease data for the bDMARD-naïve and TNFi-experienced patients are shown in Table [1](#Tab1){ref-type="table"}. In general, the TNFi-experienced patients had numerically higher levels for most measures, which was indicative of them having more severe disease at baseline compared with bDMARD-naïve patients.Table 1Baseline disease characteristics for bDMARD-naïve and TNFi-experienced patients in COAST-V and COAST-WCOAST V: bDMARD-naïve\
*N = * 341COAST-W: TNFi-experienced\
*N =  *316ASAS treatment response domains Patient global7.0 (1.6)7.9 (1.7) Spinal pain7.2 (1.5)7.9 (1.5) Inflammation (BASDAI Q5/Q6)6.7 (1.7)7.3 (1.7) BASFI6.2 (2.0)7.3 (1.7)Other outcomes Spinal pain at night7.0 (1.6)7.7 (1.7) Fatigue (BASDAI Q1)7.1 (1.6)7.7 (1.4) Fatigue (NRS)6.8 (1.7)7.3 (1.8) JSEQ8.2 (5.2)10.4 (5.6) BASDAI6.7 (1.4)7.4 (1.3) SF-36 PCS33.4 (8.0)28.6 (7.9)Data shown as mean (SD)*ASAS* Assessment of Spondyloarthritis International Society, *BASDAI* Bath Ankylosing Spondylitis Disease Activity Index, *BASFI* Bath Ankylosing Spondylitis Functional Index, *bDMARD* biologic disease-modifying antirheumatic drugs, *JSEQ* Jenkins Sleep Evaluation Questionnaire, *NRS* Numeric Rating Scale, *SF-36 PCS* Medical Outcomes Study 36-Item Short-Form Health Survey Physical Component Summary, *SD* standard deviation, *TNFi* tumor necrosis factor inhibitor

Improvement in Pain, Fatigue, Inflammation, Sleep, and Quality of Life with Ixekizumab {#Sec9}
--------------------------------------------------------------------------------------

To determine the effect of ixekizumab specifically on the ASAS treatment response domains, the outcomes of the four domains were compared. Compared with placebo, patients treated with ixekizumab had greater improvements in patient global (Fig. [1](#Fig1){ref-type="fig"}a, b), spinal pain (Fig. [1](#Fig1){ref-type="fig"}c, d), inflammation (Fig. [1](#Fig1){ref-type="fig"}e, f), and function (BASFI) (Fig. [1](#Fig1){ref-type="fig"}g; \[[@CR13]\]) throughout the 16 weeks assessed (Table [2](#Tab2){ref-type="table"}; Fig. [1](#Fig1){ref-type="fig"}, *p* \< 0.01). The data for function in TNFi-experienced patients have been published previously \[[@CR13]\]. Patients who were bDMARD-naïve and treated with the active reference adalimumab also showed significant improvements in the ASAS treatment response domains when compared with placebo. Improvements with ixekizumab treatment in the ASAS treatment response domains were consistent between the bDMARD-naïve and TNFi-experienced patients, with significant improvements reported as early as week 1 (*p* \< 0.01) \[[@CR13]\].Fig. 1Least-squares mean (LSM) changes from baseline in the ASAS treatment response domains of **a**, **b** patient global, **c**, **d** spinal pain, **e**, **f** inflammation (BASDAI Q5 and Q6), and **g** function (BASFI) for **a**, **c**, **e**, **g** bDMARD-naïve patients (COAST-V) and **b**, **d**, **f** TNFi-experienced patients (COAST-W). Comparisons with PBO were made using a mixed-effects model for repeated measures. \*\*\**p* \< 0.001 vs. PBO; \*\**p* \< 0.01 vs. PBO. The BASFI data for TNFi-experienced patients (COAST-W) were published previously \[[@CR13]\]. *ADA* adalimumab, *ASAS* Assessment of Spondyloarthritis International Society, *BASDAI* Bath Ankylosing Spondylitis Disease Activity Index, *BASFI* Bath Ankylosing Spondylitis Functional Index, *bDMARD* biologic disease-modifying antirheumatic drugs, *IXE* ixekizumab, *PBO* placebo, *Q2W*, every 2 weeks, *Q4W* every 4 weeks, *TNFi* tumor necrosis factor inhibitorTable 2Changes from baseline in patient-reported outcomes for bDMARD-naïve (COAST-V) and TNFi-experienced patients (COAST-W)StudyLeast-squares mean (standard error)WeekIXE Q2WIXE Q4WADAPBOASAS treatment response domains Patient global  COAST-V8− 2.4 (0.24)\*− 2.4 (0.24)\*− 2.4 (0.23)\*− 1.1 (0.24)16− 2.8 (0.25)\*− 2.5 (0.25)^γ^− 2.6 (0.24)\*− 1.4 (0.24)  COAST-W8− 2.3 (0.22)\*− 2.2 (0.20)\*--− 0.4 (0.21)16− 2.1 (0.24)\*− 2.4 (0.22)\*--− 0.7 (0.23) Spinal pain  COAST-V8− 2.7 (0.23)\*− 2.8 (0.24)\*− 2.5 (0.23)\*− 1.2 (0.23)16− 3.2 (0.24)\*− 3.2 (0.25)\*− 2.7 (0.23)^γ^− 1.7 (0.24)  COAST-W8− 2.4 (0.23)\*− 2.3 (0.20)\*--− 0.6 (0.21)16− 2.5 (0.25)\*− 2.4 (0.23)\*--− 1.0 (0.24) Inflammation (BASDAI Q5 and Q6)  COAST-V8− 2.6 (0.22)\*− 2.6 (0.22)\*− 2.4 (0.21)\*− 1.2 (0.22)16− 2.9 (0.23)\*− 3.2 (0.24)\*− 2.7 (0.22)\*− 1.3 (0.23)  COAST-W8− 2.2 (0.22)\*− 2.2 (0.20)\*--− 0.4 (0.21)16− 2.4 (0.25)\*− 2.4 (0.23)\*--− 0.7 (0.24) Function (BASFI)^§^  COAST-V8− 2.1 (0.20)\*− 2.0 (0.20)\*− 1.9 (0.19)\*− 0.9 (0.20)16− 2.4 (0.22)\*− 2.4 (0.22)\*− 2.1 (0.21)^γ^− 1.2 (0.22)Other outcomes Spinal pain at night  COAST-V8− 2.9 (0.24)\*− 3.1 (0.24)\*− 2.7 (0.23)\*− 1.1 (0.24)16− 3.4 (0.25)\*− 3.6 (0.26)\*− 2.9 (0.24)\*− 1.6 (0.25)  COAST-W8− 2.4 (0.24)\*− 2.3 (0.22)\*--− 0.5 (0.23)16− 2.5 (0.26)\*− 2.6 (0.24)\*--− 1.0 (0.25) Fatigue (BASDAI Q1)  COAST-V8− 2.0 (0.23)^†^− 2.4 (0.23)\*− 2.1 (0.22)^γ^− 1.2 (0.22)16− 2.5 (0.24)\*− 2.6 (0.24)\*− 2.3 (0.23)^γ^− 1.4 (0.23)  COAST-W8− 1.8 (0.21)\*− 1.7 (0.19)\*--− 0.6 (0.20)16− 2.0 (0.24)\*− 1.9 (0.22)^γ^--− 0.9 (0.23) Fatigue NRS  COAST-V8− 1.7 (0.23)^†^− 2.0 (0.23)^γ^− 2.1 (0.22)\*− 0.9 (0.22)16− 2.1 (0.24)^†^− 2.5 (0.24)^γ^− 2.2 (0.23)^†^− 1.4 (0.23)  COAST-W8− 1.5 (0.23)^γ^− 1.8 (0.21)\*--− 0.5 (0.22)16− 1.7 (0.25)^γ^− 2.0 (0.23)\*--− 0.7 (0.24) Sleep (JSEQ)  COAST-V8− 2.4 (0.42)\*− 2.1 (0.42)^γ^− 1.5 (0.40)^†^− 0.4 (0.41)16− 3.0 (0.42)^†^− 2.5 (0.43)− 2.7 (0.40)^†^− 1.5 (0.41)  COAST-W8− 2.0 (0.52)− 2.6 (0.47)^†^--− 0.9 (0.49)16− 2.4 (0.52)− 3.0 (0.48)--− 1.8 (0.50) BASDAI^§^  COAST-V8− 2.3 (0.21)\*− 2.4 (0.21)\*− 2.2 (0.20)^γ^− 1.3 (0.21)16− 2.7 (0.22)\*− 2.9 (0.22)\*− 2.5 (0.21)\*− 1.4 (0.22) SF-36 PCS^§^  COAST-V86.4 (0.74)\*6.5 (0.75)\*6.2 (0.71)\*2.0 (0.73)168.0 (0.77)\*7.7 (0.78)\*6.9 (0.73)^γ^3.6 (0.75)*ADA* adalimumab, *AS* ankylosing spondylitis, *ASAS* Assessment of Spondyloarthritis International Society, *BASDAI* Bath Ankylosing Spondylitis Disease Activity Index, *BASFI* Bath Ankylosing Spondylitis Functional Index, *bDMARD* biologic disease-modifying antirheumatic drugs, *IXE* ixekizumab, *JSEQ* Jenkins Sleep Evaluation Questionnaire, *NRS* Numeric Rating Scale, *PBO* placebo, *Q2W* every 2 weeks, *Q4W* every 4 weeks, *SF-36 PCS* Medical Outcomes Study 36-Item Short-Form Health Survey Physical Component Summary, *TNFi* tumor necrosis factor inhibitor\**p* \< 0.001 vs PBO; ^γ^*p* \< 0.01 vs PBO; ^†^*p* \< 0.05 vs PBO. Comparisons were performed using a mixed-effects model for repeated measures^§^BASFI, BASDAI, and SF-36 PCS data for TNFi-experienced (COAST-W) patients were published previously \[[@CR13]\]

Patient-reported outcomes outside of the ASAS treatment response domains were also analyzed. Compared with placebo, patients treated with ixekizumab reported greater improvements from baseline for both spinal pain at night (Fig. [2](#Fig2){ref-type="fig"}a, b; Table [2](#Tab2){ref-type="table"}; *p* \< 0.001) and fatigue assessed using BASDAI Q1 (Fig. [2](#Fig2){ref-type="fig"}c, d; Table [2](#Tab2){ref-type="table"}; *p* \< 0.05). These significant improvements with ixekizumab treatment were seen as early as week 1 and remained higher than placebo through at least week 16 (Fig. [2](#Fig2){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}; *p* \< 0.05). The results were consistent between the bDMARD-naïve patients and the TNFi-experienced patients (Fig. [2](#Fig2){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). Patients also reported greater improvements in fatigue at weeks 8 and 16 when measured by the Fatigue NRS \[[@CR22]\] (Fig. [2](#Fig2){ref-type="fig"}e, f; Table [2](#Tab2){ref-type="table"}; *p* \< 0.05). In bDMARD-naïve patients, there was a significant improvement in sleep quality at weeks 8 and 16 for patients treated with ixekizumab Q2W, and at week 8 for patients treated with ixekizumab Q4W (Fig. [2](#Fig2){ref-type="fig"}g; Table [2](#Tab2){ref-type="table"}; *p* \< 0.05). In the TNFi-experienced population, numerical improvements in sleep quality were observed for both ixekizumab dosing regimens, and a significant improvement was observed in patients treated with ixekizumab Q4W at week 8 (Fig. [2](#Fig2){ref-type="fig"}h; Table [2](#Tab2){ref-type="table"}; *p* \< 0.05).Fig. 2Least-squares mean (LSM) changes from baseline in patient-reported outcomes of **a**, **b** spinal pain at night, **c**, **d** fatigue measured by BASDAI Q1, **e**, **f** fatigue measured by NRS, and **g**, **h** sleep quality measured by JSEQ for **a**, **c**, **e**, **g** bDMARD-naïve patients (COAST-V) and **b**, **d**, **f**, **h** TNFi-experienced patients (COAST-W). Comparisons with PBO were made using a mixed-effects model for repeated measures. \*\*\**p* \< 0.001 vs. PBO; \*\**p* \< 0.01 vs. PBO; \**p* \< 0.05 vs. PBO. *ADA* adalimumab, *BASDAI* Bath Ankylosing Spondylitis Disease Activity Index, *bDMARD* biologic disease-modifying antirheumatic drugs, *IXE* ixekizumab, *JSEQ* Jenkins Sleep Evaluation Questionnaire, *NRS* Numeric Rating Scale, *PBO* placebo, *Q2W*, every 2 weeks, *Q4W* every 4 weeks, *TNFi* tumor necrosis factor inhibitor

To determine the impact of ixekizumab on overall disease activity, improvements in BASDAI were compared between the treatment arms. In bDMARD-naïve patients, patients reported significantly greater improvements in BASDAI scores with ixekizumab treatment than placebo (Fig. [3](#Fig3){ref-type="fig"}a; Table [2](#Tab2){ref-type="table"}; *p* \< 0.01). The data for BASDAI in TNFi-experienced patients have been published previously \[[@CR13]\]. The impact of ixekizumab treatment on health-related QoL was assessed using SF-36 PCS scores. Patients who were bDMARD-naïve reported greater improvements in health-related QoL when treated with ixekizumab, with significant differences observed versus placebo starting at week 4, the first time SF-36 PCS was measured after baseline, and continuing to week 16 (Fig. [3](#Fig3){ref-type="fig"}b, *p* \< 0.01). The data for SF-36 PCS in TNFi-experienced patients have been published previously \[[@CR13]\].Fig. 3Least-squares mean (LSM) changes from baseline in **a** Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and **b** Medical Outcomes Study 36-Item Short-Form Health Survey Physical Component Summary (SF-36 PCS) in bDMARD-naïve patients (COAST-V). Comparisons with PBO were made using a mixed-effects model for repeated measures. \*\*\**p* \< 0.001 vs. PBO; \*\**p* \< 0.01 vs. PBO. BASDAI and SF-36 PCS data for TNFi-experienced patients (COAST-W) were published previously \[[@CR13]\]. *ADA* adalimumab, *bDMARD* biologic disease-modifying antirheumatic drug, *IXE* ixekizumab, *PBO* placebo, *Q2W* every 2 weeks, *Q4W* every 4 weeks, *TNFi* tumor necrosis factor inhibitor

ASAS40 is Associated with Reduced Pain, Fatigue, and Sleep, and Improved QoL {#Sec10}
----------------------------------------------------------------------------

The data presented thus far indicate that significant improvements were observed in the four ASAS treatment response domains plus spinal pain at night, fatigue, QoL, and, to a lesser degree, sleep quality. However, the primary endpoint in these studies was achievement of ASAS40, a composite measure not routinely used in clinical practice. To assess the relative benefit of achieving different levels of ASAS response, data for all study arms were pooled and then divided into three groups: ASAS20 nonresponders, patients achieving ASAS20 but not ASAS40, and ASAS40 responders. Because the measures for spinal pain at night, fatigue (NRS), sleep quality, and SF-36 PCS were not used to derive ASAS40, these patient-reported outcomes were compared between the three response groups. As expected, the greatest improvements at week 16 were observed in the patients who achieved ASAS40. When compared to the ASAS20 nonresponders, bDMARD-naïve patients who achieved ASAS40 had significantly greater improvements from baseline for spinal pain at night (1.0 vs. 5.1, *p* \< 0.0001), fatigue (0.6 vs. 3.8, *p* \< 0.0001), sleep quality (1.1 vs. 4.0, *p* \< 0.0001), and SF-36 PCS (2.6 vs. 11.6, *p* \< 0.0001) (Fig. [4](#Fig4){ref-type="fig"}). These results corresponded to a 4.1-fold improvement in spinal pain at night, a 5.3-fold improvement for fatigue, a 2.6-fold improvement in sleep quality, and a 3.5-fold improvement in health-related QoL. Interestingly, the benefit of achieving an ASAS40 response occurred irrespective of previous exposure to bDMARDs. Compared with ASAS20 nonresponders, TNFi-experienced patients with AS who achieved ASAS40 also had significantly greater improvements from baseline for spinal pain at night (0.5 vs. 5.4, *p* \< 0.0001), fatigue (0.2 vs. 3.9, *p* \< 0.0001), sleep quality (0.8 vs. 4.9, *p* \< 0.0001), and SF-36 PCS (1.2 vs. 12.6, *p* \< 0.0001) (Fig. [4](#Fig4){ref-type="fig"}). These results corresponded to a 9.8-fold improvement in spinal pain at night, a 18.5-fold improvement for fatigue, a 5.1-fold improvement in sleep quality, and a 9.5-fold improvement in health-related QoL. Nearly identical results were observed when the analysis was conducted with only ixekizumab-treated patients (data not shown).Fig. 4Association between ASAS20 and ASAS40 and LSM improvement from baseline for **a** spinal pain at night, **b** fatigue (NRS), **c** sleep quality (JSEQ), and **d** SF-36 PCS at week 16. Treatment groups, including the placebo and adalimumab arms, were pooled and separated by ASAS20 and ASAS40 achievement.*Black bars* indicate data from bDMARD-naïve patients (COAST-V);*gray bars* indicate data from TNFi-experienced patients (COAST-W). ^§^*p* ≤ 0.001, achieved ASAS20 but not ASAS40 vs. ASAS20 not achieved; \**p* \< 0.0001, ASAS40 achieved vs. ASAS20 not achieved; ^†^*p* \< 0.0001, ASAS40 achieved vs. achieved ASAS20 but not ASAS40. Results were compared using ANCOVA after correcting for baseline value, age, and gender. Missing data were imputed using nonresponder imputation for the ASAS treatment response criteria and using modified baseline observation carried forward for the outcomes at week 16. Numbers shown are LSM improvements from baseline. Fold difference = \[(ASAS40 achieved/ASAS20 not achieved) − 1\]. *ANCOVA* analysis of covariance, *ASAS* Assessment of Spondyloarthritis International Society, *bDMARD* biologic disease-modifying antirheumatic drug, *JSEQ* Jenkins Sleep Evaluation Questionnaire, *LSM* least-squares mean, *n*, number of non-missing observations, *NRS* Numeric Rating Scale, *SF-36 PCS* Medical Outcomes Study 36-Item Short-Form Health Survey Physical Component Summary, *TNFi* tumor necrosis factor inhibitor

Discussion {#Sec11}
==========

The primary endpoint for both the COAST-V and COAST-W clinical trials was achievement of ASAS40. Results from these studies have been published previously, showing that ASAS40 was achieved by 48--52% of bDMARD-naïve patients and 25--31% of TNFi-experienced patients who were treated with the two dosing regimens of ixekizumab, compared with 18% and 13% of patients who received placebo, respectively \[[@CR13], [@CR14]\]. In the current analysis, we reported data on the impact of ixekizumab on patient-reported outcomes and the extent to which a better ASAS response translates to improved symptoms and health-related QoL. By translating achievement of ASAS40 into clinical measures commonly used in clinical practice, we aimed to provide physicians with scientific data that will support a better understanding of the relevance of an ASAS40 level of response from the perspective of the signs and symptoms reported by patients.

Although they have overlapping meanings, the terms "disease" and "illness" refer to slightly different aspects of patient health. Measures of disease focus on biological and chemical changes in a patient's body which are outside the normal range, while illness involves the patient's perception of this state of ill health \[[@CR24]\]. Disease measures are very important in diagnosis and in the categorization of symptoms to inform treatment decisions in patients with AS. Although improvements in CRP levels or evidence of the resolution of sacroiliitis on imaging mark an improvement in the state of the disease, it is crucial to bear in mind that improvements in a patient's perception of their state of illness are extremely important. The data presented here show that ixekizumab treatment leads to greater improvements in patient-reported AS symptoms versus placebo treatment, including pain, fatigue, function, inflammation, sleep, and overall QoL.

The results in TNFi-experienced patients who were treated with ixekizumab for disease activity (BASDAI), function (BASFI), and health-related QoL (SF-36 PCS) have been published previously \[[@CR13]\]. Compared to placebo, TNFi-experienced patients treated with ixekizumab had greater levels of improvement in BASDAI, BASFI, and SF-36 PCS at each time point tested up to 16 weeks (*p* \< 0.01) \[[@CR13]\]. Because COAST-V and COAST-W were similar in design, we were able to compare the data between the trials. It was notable that most changes from baseline for bDMARD-naïve patients were numerically higher than those for TNFi-experienced patients, and that this was observed in both placebo- and ixekizumab-treated patients (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}; Table [2](#Tab2){ref-type="table"}). By analyzing differences in response between the ixekizumab and placebo groups, we identified similar changes between bDMARD-naïve and TNFi-experienced patients for spinal pain (1.5 vs. 1.4--1.5), inflammation (1.6--1.9 vs. 1.7), and fatigue (1.1--1.2 vs. 1.0--1.1), respectively (Figs. [1](#Fig1){ref-type="fig"}, [2](#Fig2){ref-type="fig"}). These results are consistent with ixekizumab producing similar improvements in symptoms in both bDMARD-naïve and TNFi-experienced patients.

ASAS40 is a challenging endpoint to achieve that requires a high level of improvement in the patient's illness, as it is defined as improvements of ≥ 40% and ≥ 2 points in three of the four domains. These four domains represent different symptoms of AS: overall disease, pain, inflammation/stiffness, and function. Although achieving ASAS40 likely represents a significant improvement in disease activity, the ASAS treatment response criteria focus on the patient's perception of improvement in symptoms and the impact that feeling better has on their ability to function. The focus on the patient's perspective and the high bar represented by ASAS40 make it a meaningful and worthy treatment goal.

Not surprisingly, the data presented here show that achieving ASAS40 equated with significant improvements in patient symptoms. The advantage of this analysis was the ability to translate these improvements into more routinely used clinical assessments. Specifically, compared with ASAS20 nonresponders, bDMARD-naïve patients who achieved ASAS40 at 16 weeks reported greater improvements in spinal pain at night (5.1-fold), fatigue (5.3-fold), sleep quality (2.6-fold), and health-related QoL (3.5-fold) versus ASAS20 nonresponders (Fig. [4](#Fig4){ref-type="fig"}). Similarly, TNFi-experienced patients who achieved ASAS40 reported greater improvements in spinal pain at night (9.8-fold), fatigue (18.5-fold), sleep quality (5.1-fold), and health-related QoL (9.5-fold) versus ASAS20 nonresponders (Fig. [4](#Fig4){ref-type="fig"}).

Interestingly, the fold changes in spinal pain at night, fatigue, sleep, and health-related QoL for the TNFi-experienced patients who achieved ASAS40 were all numerically greater than those for the bDMARD-naïve patients, indicating that TNFi-experienced patients felt even greater symptom relief upon achieving ASAS40. The increased responses in TNFi-experienced patients may be due to a few differences between the studies. Compared to the bDMARD-naïve patients, the TNFi-experienced patients had longer disease durations and more severe symptoms at baseline (Table [1](#Tab1){ref-type="table"}). In addition, there were differences in the outcomes at week 16 for the ASAS20 nonresponders between the bDMARD-naïve patients and the TNFi-experienced patients (Fig. [4](#Fig4){ref-type="fig"}). The TNFi-experienced ASAS20 nonresponders reported smaller improvements in spinal pain at night, fatigue, and QoL compared to the bDMARD-naïve ASAS20 nonresponders (Fig. [4](#Fig4){ref-type="fig"}). Importantly, 89.9% of the TNFi-experienced patients in COAST-W had inadequately responded to one or two TNFis, but 25--31% were subsequently able to achieve ASAS40 when treated with ixekizumab. In this study, we found that many patients, even those who previously had inadequate responses to a TNFi, achieved substantial improvements in symptoms of pain, fatigue, sleep, and QoL if they attained an ASAS40 response with their treatment.

A strength of this analysis is that it included relatively high numbers of both bDMARD-naïve and TNFi-experienced patients from two randomized, placebo-controlled clinical trials, with more than 80 patients in each exposure group for both COAST-V (*n* = 81--90) and COAST-W (*n* = 98--114). While these were separate trials, the study designs for both were nearly identical, allowing comparisons to be made between the two populations. A limitation of this study is that the association analysis between ASAS treatment response and patient-reported outcomes was performed as a post hoc analysis of the COAST-V and COAST-W trials.

Conclusion {#Sec12}
==========

Patients with AS treated with ixekizumab achieved ASAS40 at significantly higher rates and had greater improvements in patient global, pain, function, inflammation/stiffness, fatigue, sleep, and health-related QoL versus patients receiving placebo. Importantly, compared with a failure to achieve ASAS20, achievement of ASAS40 was associated with a 2.6-fold to 18.5-fold greater improvement in pain, fatigue, sleep, and health-related QoL for bDMARD-naïve and TNFi-experienced patients.
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